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Background: Protein farnesylation is an important tosttranslational modification in fungi. We evaluated the
antifungal activity of two farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida.
Methods: Disk diffusion assay and broth microdilution assay were used to determine the antifungal susceptibility
of two farnesyltransferase inhibitors (manumycin A and tipifarnib) against clinical isolates of Aspergillus and Candida.
Results: Disk diffusion assay demonstrated both agents had activity against Aspergillus and Candida. The
minimal inhibitory concentration (MIC) ranges for manumycin A against Aspergillus and Candida were 200 to
400 μM and 13 to >25 μM, respectively. Unfortunately, the MIC were vastly higher than the concentrations that
inhibit the proliferation and viability of mammalian cells. The MICs of tipifarnib against Aspergillus and Candida
were >1600 μM.
Conclusion: The outcome of present study showed that farnesyltransferase inhibitors have activity against
Aspergillus and Candida. This suggests that farnesyltransferase may be used as anifungal target in designing
and developing new drugs.
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Opportunistic fungal infections, mainly caused by the
mold Aspergillus and yeast Candida, are life-threatening
in immunocompromised individuals [1,2]. The infections
continue to be a serious medical concern and are treated
by only a limited number of antifungals: polyenes, azoles,
echinocandins, and antimetabolites (flucytosine) [3]. Al-
though these drugs are now being used in the prophylaxis
and treatment of invasive fungal infection, the number of
deaths due to invasive fungal infections remains high. Fur-
thermore antifungal resistance and drug toxicity often
limit the use of these drugs [3-5]. Therefore, it is needed
to discover novel and effective antifungal agents to im-
prove the prognosis of invasive fungal infections.* Correspondence: fanghongzy@sina.com
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stated.Farnesylation is a posttranslational process that occurs
by formation of cysteine thioethers with farnesyl at or near
the C-terminus. Farnesyltransferase is a ubiquitous enzyme
that catalyzes posttranslational lipidation of the C
terminus of more than 60 important signaling proteins in
mammalian cells [6]. Several farnesyltransferase inhibitors
have been successfully developed as anticancer drugs [6].
In human pathogenic fungi, homologues of farnesyl-
transferase were identified [7]. It has been reported that
farnesyltransferase inhibitors result in growth reduction of
Cryptococcus neoformans [8]. Deletion of genes encoding
farnesyltransferase subunit leads to death of C. neoformans
and Candida albicans and growth defect in C. glabrata
[9-11]. Therefore, this enzyme may be a new target for the
development of antifungal agents. In this study, we find
that farnesyltransferase inhibitors have in vitro antifungal
activity against clinical isolates of Aspergillus and Candida,
two important human opportunistic pathogenic fungi. Re-
sults of this study may contribute to the development of
new antifungals.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Molecular structures of (a) Manumycin A and (b)
tipifarnib. Although both of the chemicals have anti-farnesylation
activity, there molecular structures are quite different.
Figure 2 Representative effect of manumycin A on the growth
of Aspergillus fumigatus. 2 × 105 conidia of A. fumigatus-1 in
200 μl suspension were spread uniformly onto minimal medium
agar plate. A 6-mm-diameter paper disk impregnated with 10 μl
(20 mM) manumycin A was placed onto the center of the inoculated
agar plate. The plate was then incubated at 35°C, and the diameter
of the zone of inhibition was measured at 48 h.
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Reagents and antifungals
The farnesyltransferase inhibitors (Figure 1) manumycin A
(Enzo Life Science International, Inc., USA; molecular
weight, 550.7) and tipifarnib (Selleck Chemicals LLC, USA;
molecular weight, 489.4) were dissolved in 100% dimethyl
sulphoxide. Reference powders of itraconazole, voricona-
zole, caspofungin, and amphotericin B were provided by
their respective manufacturers.Clinical fungal isolates
Clinical fungal isolates used for antifungal susceptibility in
this study were obtained from patients in The First Affili-
ated Hospital, College of Medicine, Zhejiang University.Disk diffusion assay
Disk diffusion assay was performed as described previously
[5]. A 200 μl suspension of each tested strain (1 × 106
conidia/ml) was spread uniformly onto minimal medium
plates. Blank paper disks 6-mm in diameter were impreg-
nated with 10 μl (20 mM) manumycin A or tipifarnib. After
drying, they were placed onto the center of inoculated agarplates. The plates were then incubated at 35°C, and the di-
ameters of the zones of inhibition were measured at 48 h.
Broth microdilution assay
The broth microdilution assay was done in accordance with
the Clinical and Laboratory Standards Institute (CLSI)
guidelines for filamentous fungi (CLSI document M38-A2)
and yeasts (CLSI document M27-A3) [12,13]. Stock solu-
tions were prepared in RPMI 1640 (Sigma) plates buffered
to a pH of 7.0 with 0.165 M 3-(N-morpholino) propanesul-
fonic acid (Sigma). The range of final drug concentrations
was 16 to 0.03 g/ml for itraconazole, voriconazole, caspo-
fungin and amphotericin B, and 1600 to 3 μM for manu-
mycin A and tipifarnib. The final inoculum was 0.4 × 104 to
5 × 104 cfu/mL for Aspergillus and 0.5 × 103 to 2.5 ×
103 cfu/mL for Candida. The MIC endpoints for manumy-
cin A, tipifarnib, itraconazole, voriconazole, and caspofun-
gin were designated as the lowest drug concentration that
prevented any discernible growth (complete growth inhi-
bition) for filamentous fungi or the first well that demon-
strated a prominent reduction in growth (a 50% reduction
relative to that for the growth control) for yeasts at 48 h of
incubation at 35°C. The MIC endpoints for amphotericin B
were defined as the lowest drug concentration that com-
pletely inhibited fungal growth.
C. parapsilosis ATCC 22019 were included in each
susceptibility test for quality control and assessment of
reproducibility testing [12,13]. Each assay was performed
in triplicate on three different days.
Table 1 Minimal inhibitory concentrations (MICs) of manumycin A, amphotericin B, itraconazole, and voriconazole
against Aspergillus and Candida determined by standard broth microdilution method
Amphotericin B Itroconazole Voriconazole Caspofungin Manumycin A
(μg/ml) (μg/ml) (μg/ml) (μg/ml) (μM)
A. fumigatus-1 1 0.5 0.5 0.06 200
A. fumigatus-2 1 0.5 1 0.06 400
A. fumigatus-3 1 0.25 0.5 0.06 200
A. flavus-1 1 0.5 1 0.125 200
A. flavus-2 1 0.5 1 0.125 200
A. terreus-1 2 0.5 0.5 0.06 200
C. albicans-1 0.5 0.25 0.25 1 25
C. albicans-2 1 0.25 0.5 0.5 13
C. albicans-3 1 0.5 0.5 0.5 13
C. albicans-4 0.5 0.25 0.25 1 25
C. tropicalis-1 1 0.125 0.125 0.5 13
C. tropicalis-2 1 0.25 0.125 0.5 25
C. glabrata-1 1 0.5 0.25 1 25
C. glabrata-2 1 0.25 0.125 1 25
C. krusei-1 0.5 1 0.5 0.25 25
C. krusei-2 0.5 1 0.5 0.25 25
C. parapsilosis 0.5 0.25 0.06 1 25
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Disk diffusion assay results showed that manumycin A
produced zones of growth inhibition against the A. fumi-
gatus isolates at 48 h of incubation, demonstrating the
inherent activities of manumycin A against A. fumigatus
(Figure 2). Disk diffusion assay also demonstrated that
this drug inhibited growth of A. flavus, A. terreus, and
C. albicans. The antifungal activity of manumycin A was
further determined by broth microdilution assay, which
showed that the MICs of manumycin A to 6 isolates of
Aspergillus were 200 to 400 μM and those of 11 isolates
of Candida were 13 to 25 μM (Table 1). However disk
diffusion assay showed that tipifarnib, another farnesyl-
transferase inhibitor produced unclear zones of growth
inhibition against both Aspergillus and Candida. Broth
microdilution method showed that the MICs of tipifarnib
to both Candida and Aspergillus were >1600 μM
(Table 1).
Discussion
Recently, it had been reported that farnesyltransferase in-
hibitors showed antifungal activity against Cryptococcus
[8]. In the present study, we showed that mamumycin
A can inhibit growth of Aspergillus and Candida. To
our knowledge, this is the first report of the in vitro
antifungal activity of manumycin A against Aspergillus
and Candida.
The antifungal activity of farnesyltransferase inhibitors
suggests that inhibiting or deleting RAM1 and RAM2genes should result significant defect of fungal growth
[8,9]. We also find that deletion of RAM1 gene in A.
fumigatus results in significant growth defect of this
fungus (unpublished data). Therefore fungal RAM1
and RAM2 may be a new target for design antifungal
drugs. Although the MICs of the current farnesyltrans-
ferase inhibitors to Aspergillus and Candida were
vastly high, we postulate that designing new farnesyl-
transferase inhibitors having high inhibiting effect on
fungal farnesyltransferase is promising.
Both manumycin A and tipifarnib are farnesyltransfe-
rase inhibitors, however their chemical structures are
quite different (Figure 1). This could explain why the
MICs of the two agents against fungi are quite different.
Conclusion
Our study showed that farnesyltransferase inhibitors
have activity against Aspergillus and Candida. This sug-
gests that farnesyltransferase may be used as anifungal
target in designing and developing new drugs.
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